Kezar Life Sciences (KZR) Expected to Announce Quarterly Earnings on Thursday

Kezar Life Sciences (NASDAQ:KZR) is expected to release its earnings data before the market opens on Thursday, March 13th. Analysts expect Kezar Life Sciences to post earnings of ($2.71) per share for the quarter.

Kezar Life Sciences Stock Performance

Shares of NASDAQ KZR opened at $5.86 on Thursday. Kezar Life Sciences has a 1 year low of $5.20 and a 1 year high of $10.50. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.65 and a quick ratio of 7.65. The firm has a fifty day moving average price of $6.29 and a 200-day moving average price of $6.72. The stock has a market cap of $42.75 million, a PE ratio of -0.44 and a beta of 0.49.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. William Blair reissued an “outperform” rating on shares of Kezar Life Sciences in a research note on Friday, February 28th. Wells Fargo & Company lowered their target price on shares of Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 19th. Finally, HC Wainwright reissued a “neutral” rating on shares of Kezar Life Sciences in a research report on Monday, December 2nd.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.